We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Testing Targets Risk Factor for Colon Cancer

By LabMedica International staff writers
Posted on 31 May 2011
A screening procedure has been developed that radically increases testing for Lynch syndrome, a hereditary genetic disorder that increases cancer risk. More...


Paraffin-embedded biopsies from cancerous tissue can be examined for certain mutations in genes that repair DNA by testing different DNA markers for irregularities.

Pathologists at the Mayo Clinic (Rochester, MN, USA) tested all resected newly diagnosed colorectal cancers in patients who were less than 51 years of age, from 2003 to 2008. All the patients automatically underwent polymerase chain reaction (PCR)-based microsatellite instability (MSI) testing if there was no testing prior to surgical resection. In MSI, DNA is isolated from normal and cancer tissue is then PCR-amplified across mononucleotide microsatellites and analyzed by fluorescent capillary electrophoresis. Allelic profiles from the normal and malignant tissue are compared to determine the MSI status which is reported as microsatellite instability high (MSI-H), an abnormal result, or microsatellite instability low or stable (MSI-L or MSS), both normal results. Patients with a history of inflammatory bowel disease or polyposis syndrome were excluded.

Over the five-year period, 210 of 258 newly diagnosed young patients undergoing surgery, 128 had preoperative and 82 postoperative testing. Of the 48 not tested, 29 eligible for postoperative reflex testing were missed, 15 had a complete pathological response after neoadjuvant therapy, and four refused. Of the 210 patients tested, 28 had MSI-H tumors. Similar numbers of MSI-H were captured, 14.8% preoperatively and 11% postoperatively. Overall, 88% of the high-risk group had tests, and the protocol caught 11% of MSI-H tumors that would have otherwise been missed. An estimated 3% of colon cancers can be attributed to Lynch syndrome. At least 80% of people with Lynch syndrome develop colorectal cancer, many of them before the age of 50.

MSI is a key factor in several cancers including colorectal, endometrial, ovarian, and gastric cancers. Colorectal cancer studies have demonstrated two mechanisms for MSI occurrence. In both cases, microsatellite insertions and deletions within tumor suppressor gene coding regions result in uncontrolled cell division and tumor growth. As a result of this testing, cancer may be caught earlier and physicians may be more proactive in treatment. The testing should be done before surgery, because a diagnosis may change the course of treatment. Testing after surgery also is beneficial as the knowledge gleaned can affect future care for patients and their families. The study was presented at the American Society of Colon and Rectal Surgeons Annual Scientific Meeting, held May 14-18, 2011, in Vancouver (BC, Canada).

Related Links:
Mayo Clinic




New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.